Iminostilbene

Iminostilbene is a chemical precursor of carbamazepine. Additionally, Iminostilbene is an orally active inhibitor of PKM2 (Pyruvate Kinase M2) and COX2 (Cyclooxygenase-2) . Iminostilbene exerts its effects by inhibiting PKM2 and its interaction with HIF-1α and STAT3, reducing COX2 and iNOS expression, and decreasing LPS-induced release of IL-1β, IL-6, TNF-α, and MCP-1, thereby suppressing macrophage-mediated inflammatory responses and improving myocardial ischemia/reperfusion (MI/R) injury. Iminostilbene holds promise for research in inflammation regulation, cardiovascular diseases (such as MI/R injury), and macrophage-mediated immune-related diseases[1][2].

Product Specifications

CAS Number

[256-96-2]

UNSPSC

12352005

Hazard Statement

H302, H401, H411

Target

COX; HIF/HIF Prolyl-Hydroxylase; Interleukin Related; NO Synthase; Pyruvate Kinase; STAT; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; JAK/STAT Signaling; Metabolic Enzyme/Protease; Stem Cell/Wnt

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/iminostilbene.html

Purity

99.34

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

C12=CC=CC=C1C=CC3=CC=CC=C3N2

Molecular Formula

C14H11N

Molecular Weight

193.25

Precautions

H302, H401, H411

References & Citations

[1]Christian P, et al. Crystallization of Carbamazepine in Proximity to Its Precursor Iminostilbene and a Silica Surface. Cryst Growth Des. 2016 May 4;16 (5) :2771-2778. Epub 2016 Mar 30.|[2]Lu S, et al. Iminostilbene, a novel small-molecule modulator of PKM2, suppresses macrophage inflammation in myocardial ischemia-reperfusion injury. J Adv Res. 2020 Sep 9;29:83-94.